

Koji Ogawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10050426/publications.pdf>

Version: 2024-02-01

57
papers

1,157
citations

393982

19
h-index

433756

31
g-index

58
all docs

58
docs citations

58
times ranked

1303
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
2	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.	1.1	17
3	Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449.	1.6	9
4	The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 508-521.	1.8	1
5	Questionnaire survey on hepatitis virus tests among ophthalmologists in Japan. <i>Acta Hepatologica Japonica</i> , 2022, 63, 87-89.	0.0	1
6	Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon- λ 3 induction in chronic hepatitis B patients. <i>Hepatology Research</i> , 2022, 52, 586-596.	1.8	4
7	Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , .	1.8	4
8	Tenofovir- α -disoproxil- α -fumarate modulates lipid metabolism via hepatic CD36/PPAR- α activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	2.3	29
9	Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass. <i>Journal of Viral Hepatitis</i> , 2021, 28, 755-763.	1.0	6
10	Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals. <i>Internal Medicine</i> , 2021, 60, 337-343.	0.3	10
11	Present status of hepatitis medical care coordinators in regional core centers in Japan. <i>Acta Hepatologica Japonica</i> , 2021, 62, 96-98.	0.0	3
12	Serum fatty acid-binding protein 5 is a significant factor in hepatocellular carcinoma progression independent of tissue expression level. <i>Carcinogenesis</i> , 2021, 42, 794-803.	1.3	4
13	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3
14	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.	1.6	8
15	Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas. <i>Hepatology Research</i> , 2021, 51, 870-879.	1.8	8
16	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.	1.7	8
17	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
18	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.	1.7	10

#	ARTICLE	IF	CITATIONS
19	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <i>Hepatology Research</i> , 2021, 51, 725-749.	1.8	90
20	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 593-619.	2.3	158
21	Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals. <i>Scientific Reports</i> , 2021, 11, 16616.	1.6	6
22	Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. <i>Supportive Care in Cancer</i> , 2020, 28, 3251-3257.	1.0	5
23	Hepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. <i>Hepatology Research</i> , 2020, 50, 182-189.	1.8	8
24	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.	0.6	8
25	Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161.	2.3	4
26	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35
27	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	1.4	22
28	Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people. <i>Hepatology Research</i> , 2020, 50, 715-725.	1.8	28
29	High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681.	1.8	20
30	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.	2.3	19
31	Nutrition is often ignored in management of chronic liver diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1127-1128.	1.4	1
32	Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.	1.8	32
33	Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.	1.8	8
34	Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. <i>Journal of Proteome Research</i> , 2019, 18, 3133-3141.	1.8	12
35	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.	0.3	5
36	Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of 1,2,3-Linked Sialic Acid Residues. <i>Analytical Chemistry</i> , 2019, 91, 13343-13348.	3.2	12

#	ARTICLE	IF	CITATIONS
37	Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 810-822.	1.8	27
38	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.	2.3	21
39	Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. <i>Acta Hepatologica Japonica</i> , 2019, 60, 397-404.	0.0	0
40	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.	0.3	4
41	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.	1.8	15
42	Treatment of hepatitis C in special populations. <i>Journal of Gastroenterology</i> , 2018, 53, 591-605.	2.3	26
43	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128.	2.3	49
44	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154.	1.8	1
45	L-carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 910-922.	2.0	67
46	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.	1.8	21
47	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388.	1.1	12
48	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.	2.3	32
49	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136.	1.8	31
50	Hepatitis B virus X protein impairs interferon signaling via upregulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , 2017, 89, 267-275.	2.5	29
51	Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866.	2.5	20
52	Combination of neutrophil-to-lymphocyte ratio and early desinhibin carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541.	1.8	13
53	A case of hepatic inflammatory pseudotumor with time-dependent contrast-enhanced ultrasonography findings. <i>Choonpa Igaku</i> , 2017, 44, 447-455.	0.0	0
54	Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303.	1.8	27

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740.	2.3	103
56	ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 593-599.	1.0	17
57	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 320-327.	0.7	18